Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro.
Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro.
复制标题
生长激素释放因子生长分泌素在体外释放垂体生长激素。
DOI：
10.1073/pnas.79.24.7909
复制
发表时间：
1982
影响因子：
11.1
通讯作者：
Guillemin,R
中科院分区：
文献类型：
--
作者：
Brazeau,P;Ling,N;Böhlen,P;Esch,F;Ying,SY;Guillemin,R
纯化的(大鼠)下丘脑生长激素释放因子(GRF)，从引起肢端肥大症的胰腺胰岛细胞瘤中分离出来的天然人GRF，以及人类材料的合成复制物，是大鼠原代培养的免疫反应性生长激素(GH)的有效促分泌物。天然或合成的多肽具有相同的剂量-反应曲线，具有相同的斜率和相同的最大效应。肿瘤来源的GRF的中位有效剂量为15×10(-12)M。下丘脑的GRF或肿瘤来源的GRF的合成复制的效果是立即的，在与垂体细胞灌流系统接触后不到30秒就能表现出来。下丘脑GRF或肿瘤来源的GRF对刺激免疫反应性生长激素的释放具有高度特异性；对其他垂体激素的分泌没有明显的伴随影响。生长抑素-28和生长抑素-14在典型的非竞争性拮抗中抑制下丘脑GRF或肿瘤源性GRF产生的生长激素的释放。根据本文报道的结果，在体外，下丘脑GRF和肿瘤来源的GRF在刺激免疫反应性生长激素分泌方面的能力是无法区分的。建议用“躯体分泌素”来代替首字母缩写GRF。
Purified (rat) hypothalamic growth hormone releasing factor (GRF), native human GRF isolated from an islet cell tumor of the pancreas that had caused acromegaly, and the synthetic replicates of the human material are potent secretagogues of immunoreactive growth hormone (GH) by primary cultures of rat pituitary cells. Native or synthetic peptides give identical dose-response curves, with identical slopes and identical maximal effects. The median effective dose of the tumor-derived GRF is 15 x 10(-12) M. The effect of hypothalamic GRF or of a synthetic replicate of tumor-derived GRF is immediate, being demonstrable in less than or equal to 30 sec after contact in a pituitary cell perifusion system. The effect of hypothalamic GRF or of tumor-derived GRF is highly specific for stimulating release of immunoreactive growth hormone; there is no demonstrable concomitant effect on the secretion of other pituitary hormones. Somatostatin-28 and somatostatin-14 inhibit the release of growth hormone produced by hypothalamic GRF or tumor-derived GRF in typical noncompetitive antagonism. On the basis of the results reported here, hypothalamic GRF and tumor-derived GRF are qualitatively indistinguishable in their ability to stimulate the secretion of immunoreactive growth hormone in vitro. The name "somatocrinin" is proposed to replace the acronym GRF.